Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

US breast cancer patient registry study: CAPTURE (Compliance and Preference for Tamoxifen Registry)

Trial Profile

US breast cancer patient registry study: CAPTURE (Compliance and Preference for Tamoxifen Registry)

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Mar 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tamoxifen (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms CAPTURE
  • Sponsors Fortovia Therapeutics
  • Most Recent Events

    • 13 Mar 2014 Status changed from recruiting to active, no longer recruiting based on information reported in a DATA BioSciences media release.
    • 13 Mar 2014 Results will be presented at the National Comprehensive Cancer Network (NCCN) 19th Annual Conference: Advancing the Standard of Cancer Care according to a DARA BioSciences media release. Results were also reported in the media release.
    • 14 Aug 2013 DARA BioSciences has enrolled 13 US oncology centres and completed nearly 50% of the patient surveys in this registry, according to a company media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top